The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer

• Published in: European journal of surgical oncology 2005-03, Vol.31 (2), p.164-169
• Main Authors: Ni, X.G., Bai, X.F., Mao, Y.L., Shao, Y.F., Wu, J.X., Shan, Y., Wang, C.F., Wang, J., Tian, Y.T., Liu, Q., Xu, D.K., Zhao, P.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Ampulla of Vater - metabolism; Ampulla of Vater - pathology; Antigens, Tumor-Associated, Carbohydrate - blood; Bile Duct Neoplasms - blood; Bile Duct Neoplasms - diagnosis; Bile Duct Neoplasms - surgery; Bile Ducts, Extrahepatic - metabolism; Bile Ducts, Extrahepatic - pathology; Bilirubin - blood; Biomarkers, Tumor - blood; CA-19-9 Antigen - blood; CA19-9; CA242; Carcinoembryonic Antigen - blood; Carcinoma, Islet Cell - blood; Carcinoma, Islet Cell - diagnosis; Carcinoma, Islet Cell - surgery; CEA; Cholangiocarcinoma - blood; Cholangiocarcinoma - diagnosis; Cholangiocarcinoma - surgery; Female; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic cancer; Pancreatic Neoplasms - blood; Pancreatic Neoplasms - diagnosis; Pancreatic Neoplasms - surgery; Pancreaticoduodenectomy; Prognosis; Sensitivity and Specificity; Statistics as Topic; Survival Analysis; Treatment Outcome; Tumour markers
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2004.09.007

Serum tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA242 were investigated to evaluate the values of single and combined test in the diagnosis and prognosis of pancreatic cancer. Pre-operative serum CEA, CA19-9 and CA242 were measured in 105 pancreatic cancers, 70 non-pancreatic malignancies and 30 benign pancreatic diseases. The sensitivity of CA19-9 alone was the highest in pancreatic cancer patients (80%), but the specificity was significantly lower than that of CEA and CA242 ( P